Google News

Full Coverage

Sage Therapeutics to be acquired by Supernus Pharmaceuticals

Top news

Sage Therapeutics

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Jun 16

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

Jun 16

By Annalee Armstrong

Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal

Jun 16

By Al Barbarino

All coverage

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

Jun 18

news.stocktradersdaily.com

(SAGE) Investment Analysis and Advice

Jun 20

Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE)

Jun 16

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Jun 17

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating

Jun 16

The Joplin Globe

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

Jun 16

After brushing off Biogen, Mass. biotech firm finds buyer for $795M

Jun 16

By Hannah Green

Supernus enters depression drug market with up to $795 million Sage deal

Jun 16

By Padmanabhan Ananthan & Puyaan Singh

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Jun 17

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal

Jun 17

FirstWord Pharma

Having rebuffed Biogen, Sage settles on takeout by Supernus

Jun 16

The Boston Globe

Sage Therapeutics gets acquired by Maryland drugmaker for up to $795 million

Jun 16

By Stella Tannenbaum

Updated: Sage's roller coaster ends in $561M acquisition by Supernus

Jun 16

By Max Gelman

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Jun 16

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Jun 16

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN)

Jun 16

By Edmund Ingham

Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae

Jun 16

By Kevin Dunleavy

SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals

Jun 16

Zacks Investment Research

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Jun 17

insights.citeline.com

Supernus Secures Sage With CVR-Supported Deal

Jun 16

By Jessica Merrill

The Business Journals

Maryland firm outbids Biogen for Sage Therapeutics

Jun 16

By Hannah Green

Investing.com India

Sage Therapeutics shares soar after supernus acquisition deal

Jun 16

By Senad Karaahmetovic

The Pharma Letter

Supernus’ $795 million bid sufficient for Sage

Jun 16

Sage, following setbacks, to sell to Supernus for $561M

Jun 16

By Delilah Alvarado

Mugglehead Magazine

Supernus Pharmaceuticals picks up embattled Sage Therapeutics

Jun 16

By Joseph Morton

Supernus to Acquire Sage Therapeutics in $795M Deal

Jun 16

By Rihem Akkouche

Investor's Business Daily

Beleaguered Biotech Snapped Up In $561 Million Bid

Jun 16

By Allison Gatlin

After rebuffing Biogen, Sage pairs off with Supernus

Jun 16

Supernus to buy Sage for up to $795 million

Jun 16

By Katherine Davis

Pharmaceutical Technology

Supernus makes depression drug play with $795m Sage buyout

Jun 16

By Robert Barrie

Supernus Pharmaceuticals To Acquire Sage Therapeutics

Jun 16

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

Jun 16

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday

Jun 16

By Avi Kapoor

H.C. Wainwright Reiterates Neutral Rating on Sage Therapeutics (SAGE)

Jun 18

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Jun 16

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

Jun 16

Supernus enters depression drug market with up to $795 million Sage deal

Jun 16

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Develo

Jun 17

Supernus enters depression drug market with up to $795 million Sage deal

Jun 16

SAGE: Baird Adjusts Price Target on Sage Therapeutics | SAGE Stock News

Jun 20

SAGE Sees Price Target Boost Amid Acquisition News | SAGE Stock News

Jun 20

Canaccord Genuity Group Issues Positive Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price

Jun 20

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News

Jun 17

SAGE Stock Update: Truist Securities Raises Price Target | SAGE Stock News

Jun 17

Supernus Pharmaceuticals Announces Acquisition of Sage Therapeutics to Enhance CNS Portfolio and Drive Future Growth

Jun 16

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares

Jun 16

Supernus makes depression drug play with $795m Sage buyout

Jun 16

By Robert Barrie

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc. - M&A Call

Jun 16

The Business Journals

Supernus strikes deal to buy Sage Therapeutics

Jun 16

By Hannah Green

Search

Clear search

Close search

Google apps

Main menu